Zoetis — Financial Results

Revenue Grew Modestly in 2025, With Companion Animals Driving the Gains

Overall revenue growth was a relatively modest 2%, but the picture splits sharply by category. Companion animal products — think flea, tick, and pain treatments for pets — grew a healthy 5%, while livestock fell 5%, mostly because Zoetis sold off its medicated feed additive (MFA) portfolio in 2024. Excluding that divestiture, livestock revenue actually grew. Price increases of about 4% were the single biggest driver of overall growth.

Profit Margins Improved Even as Revenue Growth Slowed

Net income grew 8% — faster than revenue — because the company became more efficient. Cost of sales (the direct cost to make products) dropped as a share of revenue, helped by the MFA divestiture, price increases, and lower inventory write-offs. Put simply, the business is keeping more of each dollar it earns.

Five Key Products Generate 42% of All Revenue — Concentration Worth Noting

Zoetis's top five products — Simparica/Simparica Trio (parasite prevention), Apoquel/Apoquel Chewable (itch treatment), Cytopoint (allergy injection), Librela (dog pain), and its ceftiofur antibiotic line — together account for 42% of total revenue. While these are strong, market-leading franchises, this level of concentration means any setback — a new competitor, a safety concern, or patent expiration — on even one or two of these products could meaningfully affect results. Simparica Trio and Apoquel alone represent 28% of revenue.

Zoetis Issued $4 Billion in New Debt, Including an Unusual Convertible Note

In late 2025, the company issued a $2.0 billion convertible senior note (a type of bond that can be exchanged for company shares under certain conditions) at a very low 0.250% interest rate, plus $1.85 billion in traditional senior notes. Most of the convertible note proceeds — roughly $1.8 billion — went straight to buying back company stock. Long-term debt jumped from $5.2 billion to $9.0 billion as a result. While the company remains comfortably within its debt covenants (rules set by lenders), this is a significant increase in leverage (borrowed money relative to the business's size) that investors should monitor.

The Company Repurchased $3.2 Billion of Its Own Stock in 2025

Zoetis bought back 23.9 million of its own shares for $3.2 billion during 2025, funded partly by the new convertible note proceeds and partly by operating cash flow. A share repurchase reduces the number of shares outstanding, which mechanically boosts earnings per share (EPS) — GAAP diluted EPS rose 10% to $6.02. The board still has $2.4 billion remaining under a $6 billion buyback authorization approved in August 2024, signaling continued commitment to returning cash to shareholders.

An Accounting Calendar Change Pulled Some 2025 International Sales Forward

Zoetis is transitioning its international subsidiaries to a unified December 31 year-end (they previously reported on a November 30 cycle). To prepare, the company made operational changes that accelerated approximately 2.5%–3.5% of International segment sales into the reported fourth quarter of 2025 that would otherwise have occurred later. Management explicitly stated this is a one-time effect that will not repeat in 2026 — meaning international growth rates reported for early 2026 may look softer by comparison, even if the underlying business is performing similarly.